AVIC INTERNATIONAL MARITIME HOLDINGS LIMITED
*(Formerly known as "**AVIC International Investments Limited**")*

(Incorporated in Singapore)
(Company Registration No. 201024137N)
(the "**Company**" and together with its subsidiaries, the "**Group**")

CAPITAL INJECTION INTO JOINT VENTURE COMPANY

AVIC International Maritime Holdings Limited (the "**Company**") had on 13 November 2014 announced in its unaudited financial statements and announcement for the third quarter ended 30 September 2014 that the Group had, through its indirectly wholly-owned subsidiary, AVIC International Offshore Pte. Ltd. ("**AIO**"), formed a joint venture company in Singapore under the name of "AVIC Tidestar Fast Offshore Pte Ltd" ("**Joint Venture**") with Tides Fast Offshore Pte. Ltd. ("**JV Partner**"), an unrelated third party. AIO owns 65% of the issued shares in the capital of the Joint Venture, whereas the JV Partner owns the remaining 35%. The Joint Venture was incorporated with a view to expanding the Group's ship-trading and ship-building related business operations in the region.

The Company would like to announce that a capital injection exercise ("**Capital Injection**") has been completed today by the Company and the JV Partner, with a view to developing the operations of the Joint Venture in the following manner:

Subscriber	Number of the shares held in the capital of Joint Venture immediately before the Capital Injection/ shareholding percentage	Number of New Shares subscribed pursuant to the Capital Injection	Amount paid (US$1.00 per New Share of the Joint Venture)	Number of shares held in the capital of the Joint Venture immediately after the Capital Injection / Shareholding percentage
AIO	65 / 65%	259,935	US$259,935	260,000/ 65%
JV Partner	35/ 35%	139,965	US$139,965	140,000/ 35%
Total	100/100%	399,900	US$399,900	400,000/ 100%

Following the above, the issued and paid-up share capital of the Joint Venture is increased from US$100 to US$400,000.

The Capital Injection was funded by the Group's internal resources and is not expected to have any material impact on the earnings per share and net tangible assets per share of the Company for the financial year ending 31 December 2015.

None of the directors (other than in his capacity as director or shareholder of the Company, as the case may be) of the Company has any interest, direct or indirect in the aforesaid capital injection.

By Order of the Board

Dr Diao Weicheng
Executive Chairman
9 March 2015